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A B S T R A C T
Healthy adult volunteers received 1 g of sulphamethizole orally (n ¼ 10) and later 400 mg of
pivmecillinam (274 mg of mecillinam) (n ¼ 9). All urine was collected in defined periods over 24 h,
and the drug concentrations in urine were determined. For sulphamethizole, the maximum urine
concentration for seven subjects was reached in 0–3 h, and for the remaining three in 3–6 h. For
mecillinam, eight of the nine subjects attained a maximum urine concentration in 0–3 h, after which the
concentration declined rapidly for six subjects in 3–6 h. Strains of Escherichia coli with different MICs for
sulphamethizole and mecillinam were exposed to collected urine for 2.5 h and 5 h. The results indicated
that a sensitive E. coli population should be suppressed by sulphamethizole in urine for two-thirds of the
time (with 1 g twice-daily) and by mecillinam in urine throughout the 24-h period (with 400 mg three
times a day). There was a slight but significant correlation between the ex-vivo effect (D log10 CFU ⁄mL)
and the log10 concentration ⁄MIC ratio after exposure to sulphamethizole for 5 h (r2 ¼ 0.27, p < 0.0001),
and a significant correlation between the variables with mecillinam (r2 ¼ 0.66, p < 0.0001).
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I N T R O D U C T I O N
The sulphonamides have been used since the 1930s
in the treatment of urinary tract infection (UTI), but
have now been replaced in most of the world by
either the combination trimethoprim–sulphameth-
oxazole (introduced in 1968) or trimethoprim
alone. In Denmark, sulphamethizole is still used
as empirical treatment for uncomplicated UTI, but
mecillinam is currently being discussed as an
alternative. The therapeutic effect in UTI depends
on the concentration of the antibiotic in urine [1–3]
and the distribution of pathogen MIC values.
Despite this, the pharmacokinetic profile of
sulphamethizole is poorly described—probably
because extensive documentation was not
required in the 1930s. Studies often declare, with-
out any documentation, that the sulphamethizole
concentration in urine is sufficiently high to erad-
icate almost all bacteria. The excretion of mecilli-
nam is well documented, but only a few studies
have established the actual urine concentration
after oral administration. Therefore, this study
investigated the concentrations in urine of sul-
phamethizole and mecillinam, and the current
National Committee for Clinical Laboratory Stand-
ards breakpoints were evaluated. In addition, the
inhibitory effect of the excreted urine containing
antibiotic on susceptible and resistant strains of
Escherichia coli was measured.
M A T E R I A L S A N D M E T H O D S
In-vivo study participants
Ten healthy adult volunteers (five women, five men) partici-
pated in the study, which was approved by the local ethical
committees (Copenhagen and Frederiksberg). Each participant
was given oral and written information, and written informed
consent was obtained from each subject. No use of antibiotics
was allowed during the 2 weeks preceding the study, and all
alcohol and caffeine-containing beverages were avoided from
24 h before the study. Participants ranged from 28 to 49 years
in age, and their weights ranged from 52 to 85 kg (mean:
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68.3 kg). Creatinine clearance of the subjects was determined
from a blood sample and a 24-h urine collection; the range of
81–127 mL ⁄min (mean: 104 mL ⁄min) indicated that all had
normal kidney function. The study of the two antibiotics was
separated by 4 weeks.
Drug administration
Sulphamethizole was administered orally (two 500-mg tablets
of Sulfamethizol Ophtha; Unikem, Copenhagen, Denmark).
Sulphamethizole is excreted in the urine by an active transport
mechanism, and c. 10% is acetylated (inactive) [4]. Mecillinam
was given orally as 400 mg of pivmecillinam (two 200-mg
tablets of Selexid; Løvens Kemiske Fabrik, Ballerup, Denmark),
corresponding to a total of 274 mg of mecillinam. About 21%
of the mecillinam dose is excreted in the urine (three inactive
metabolites and one active metabolite (0.5%)). Most mecilli-
nam is excreted via the bile into the faeces [5]. The subjects
fasted from 22.00 hours on the night before drug administra-
tion, and at 07.00 hours the standard dose of antibiotic was
ingested. One hour later, they were allowed to eat and drink
(they all recorded the amount of liquid that they consumed
during the entire experiment).
Urine samples
All urine was collected, and samples were pooled in the
following intervals after antibiotic ingestion: 0 h (control),
0–3 h, 3–6 h, 6–12 h, and 12–24 h. Immediately after collection,
urine samples were placed in a refrigerator. The amount of
urine pooled in each time interval was determined by weight,
and the pH was measured by a colour-fixed indicator stick
(pH Test Strips 4.5–10; Sigma, St Louis, MO, USA). A sample
of each pool was placed in a ) 20 C freezer for further
processing.
Antibiotic concentration determination
Drug concentrations in urine were determined by the bioassay
method for mecillinam, and by spectrophotometry for sul-
phamethizole. For the bioassay, the mecillinam-sensitive E. coli
strain Leo HA2, grown on Mueller–Hinton BBL-II agar (Becton
Dickinson, Erembodegem-Aalst, Belgium), was used. Each
sample was measured in duplicate and matched to a standard
curve of six four-fold dilutions. The concentrations (pre-
pared in phosphate buffer, pH 5.0) started at 2500 mg ⁄L and
ended at 2.44 mg ⁄L (detection limit 0.5 mg ⁄L). The coefficient
of variation was 1.7–8.5%.
The spectrophotometric assay (Ultrospec 2000; Pharmacia
Biotech, Piscataway, NJ, USA) for sulphamethizole was per-
formed as described previously [6,7], with standard curves of
four two-fold dilutions starting at 200 mg ⁄L. This method does
not measure the acetylated, inactive fraction. The dilutions
were made in the control urine sample pooled from two
women and two men (randomly selected). One standard curve
based on the mean values of these four curves (coefficient of
variation 1.6–7.4%) was used to measure the concentration in
all urine samples.
Urine samples that exceeded the standard curve upper limit
were diluted before retesting. The detection limit was
2.5 mg ⁄L.
Bacteria and MICs
MICs were determined by the agar dilution method according
to National Committee for Clinical Laboratory Standards
criteria [8], using Mueller–Hinton BBL II agar. For the
sulphamethizole ex-vivo study, the following E. coli strains
were used: KMA-26883 (strain I), MIC 128 mg ⁄L; UVI-203
(strain II), MIC 512 mg ⁄L; and KMA-28523 (strain III),
MIC > 2048 mg ⁄L (sulII gene positive). For the mecillinam
ex-vivo study, the following E. coli strains were used:
21623884-114 (strain IV), MIC 0.5 mg ⁄L; 21773360-98 (strain
V), MIC 16 mg ⁄L; and Eco518 (strain VI), MIC 128 mg ⁄L. Data
on the distribution of MIC values in the E. coli population
isolated from UTIs in general practice [9] were used for
comparison with the concentrations in urine of the antibiotics.
Ex-vivo study
The bactericidal activity of urine from individuals from each
collecting period was tested against the three test strains in a
microtitre plate format (Nunc, Neerijse, Belgium). Before the
experiment, all urine samples were thawed and filtered through
a 0.45-lm filter (Millipore, Glostrup, Denmark). To each 180-lL
urine sample, a 20-lL inoculum, adjusted to 107 CFU ⁄mL in
Mueller–Hinton broth (BBL-II), was added to give a final
inoculum of 1 · 106 CFU ⁄mL and a concentration of 10% v/v
Mueller–Hinton broth. The microtitre plates were incubated in a
shaking incubator at 35 C with constant shaking (400 rev ⁄min).
Samples were taken at 0, 2.5 and 5 h for determination of viable
counts on lactose bromothymol blue agar plates (Statens Serum
Institut, Copenhagen, Denmark) by the spread plate technique
(Eddy Jet; IUL Instruments, Barcelona, Spain). After incubation
for 18–24 h, the bacterial concentration (CFU ⁄mL) was deter-
mined with a Countermat Flash (IUL Instruments). The detec-
tion limit was estimated to be 50 CFU ⁄mL.
Statistics
The paired t-test (two-tailed) and Pearson’s linear regression
analyses were used to compare the ex-vivo effects between the
E. coli strains; p values < 0.05 were considered significant
(GraphPad Prism v. 3.00 for Windows; GraphPad Software,
San Diego, CA, USA).
R E S U L T S
Antibiotic concentrations in urine
All ten participants completed the study with
sulphamethizole, but one male subject did not
participate in the study with mecillinam because
of illness. For both antibiotics, the accumulated
volume of excreted urine (mL), the urine concen-
tration (mg ⁄L) and the accumulated excreted
amount, of antibiotic (mg) are displayed in
Fig. 1. The median and range of the urine concen-
tration, accumulated excreted amount, and the
urine pH value are shown in Table 1 for the four
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collection intervals. In both experiments, there
was a marked difference in the amount of urine
excreted, which correlated well with the registered
amount of liquid consumed (data not shown).
For sulphamethizole, the maximum urine con-
centration for seven individuals was reached in
0–3 h (range: 528–1857 mg ⁄L), and for the remain-
ing three subjects in 3–6 h (range: 549–1034 mg ⁄L)
(mean T½ urine ¼ 3.36 h). There appeared to be two
patterns of excretion for sulphamethizole: five
subjects (2, 5, 6, 8 and 10) reached the highest
concentration in 0–3 h, the concentration declining
thereafter to a minimum in 3–6 h, whereas the
other five subjects attained a lower maximum
concentration that lasted for a longer period of
time. This observation was not related to the
subject’s age or gender. For seven subjects, the
concentration of sulphamethizole in the 12–24-h
samples was below the detection limit of 2.5 mg ⁄L.
Two subjects excreted c. 50% less sulphamethizole
than the rest, which seemed to be connected to the
low urine production of these two subjects. In
general c. 30% of the administered sulphamethiz-
ole dose (1 g) was excreted in 0–3 h, 60% in 3–6 h,
Fig. 1. (a) Urinary sulphamethizole excretion for ten subjects after an oral dose of 1000 mg. The accumulated volume of
urine, the urine concentration and the accumulated amount excreted are shown as functions of time. (b) Urinary
mecillinam excretion for nine subjects after an oral dose of 274 mg. The accumulated volume of urine, the urine
concentration and the accumulated amount excreted are shown as functions of time.
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and 66% in 6–12 h. The pH of the sulphamethizole
urine samples increased slightly between the 0–3-h
and 3–6-h periods, and then declined.
For mecillinam, eight of the nine subjects
attained a maximum urine concentration in
0–3 h (range: 176–1324 mg ⁄L), after which the
concentration declined rapidly in six subjects
during the 3–6-h period to 12–57 mg ⁄L (mean
T½ urine ¼ 1.79 h). The low urine production
observed in 3–6 h for subjects 4 and 6 resulted
in higher urine concentrations during this
period. Subject 9 achieved a maximum urine
concentration of 176 mg ⁄L after 3–6 h. In the 12–
24-h period, the mecillinam concentration in the
urine declined to a level below the detection
limit of 0.5 mg ⁄L. From Table 1 it can be
deduced that c. 30% of the mecillinam dose
(274 mg of mecillinam) was excreted in 0–3 h,
40% in 3–6 h, and 42% in 6–12 h. The pH of the
mecillinam urine samples increased slightly in
the 0–3-h and the 3–6-h periods, after which it
decreased.
Relationship between urine concentrations
and MICs
The relationship between the urine concentrations
of the two antibiotics and the MIC distribution for
E. coli strains from UTIs in general practice is
displayed in Fig. 2. The urine concentration of
sulphamethizole exceeded the MIC for 50% of the
strains for c. 12 h, but the concentration never
reached the MIC90 level of > 2048 mg ⁄L. The data
on mecillinam revealed that the MIC50 value of
0.5 mg ⁄L was exceeded for most subjects for 24 h,
and for 90% of the strains for c. 21 h.
Ex-vivo study
The effect of the urine samples containing
sulphamethizole and mecillinam on each set of
three E. coli strains with increasing MIC values
after exposure for 2.5 h and 5 h is shown in Fig. 3.
Overall, the reduction in viability was higher with
mecillinam than with sulphamethizole, and the
reduction in CFUs was more pronounced after
5 h than after 2.5 h. The effect generally decreased
from the first collection interval (0–3 h) to the
fourth collection interval (12–24 h), correspond-
ing to the decreasing antibiotic concentration over
time.
After incubation for 2.5 h with the urine samples
containing sulphamethizole, a minimal decrease in
CFU ⁄mL was observed in the 0–3-h sample, with a
significant difference in the effect on strain I
compared to strain III. For the remaining collection
intervals, the viable counts of all strains after
incubation for 2.5 h were almost identical to the
control. The results after incubation for 5 h showed
a significant difference between strains I and II,
and between strains II and III, in all collection
intervals. In the third and fourth collection inter-
vals, strain III started to grow like the control. A
significant difference between strains I and II was
observed only in the 6–12-h collection interval.
Strains IV and VI showed a significant differ-
ence in the CFU reduction for all mecillinam urine
samples after exposure for 2.5 h. There was a
significant difference between strains IV and V in
the 6–12-h and 12–24-h collections. Significant
differences after exposure for 5 h were observed
between all strains and in all collection intervals,
apart from strains V and VI in the first and fourth
Table 1. Human urinary excretion data for mecillinam and sulphamethizole after one oral standard dose
Collection
interval (h)
Median (range)
Mecillinam (n = 9) Sulphamethizole (n = 10)
Urine
concentration
(mg/L) (range)
Accumulated
excreted
(mg) (range)
Urine
pH value
(range)
Urine
concentration
(mg/L) (range)
Accumulated
excreted
(mg) (range)
Urine
pH value
(range)
Control (0 sample) 0 0 5.5 (5.0–6.0) 0 0 5.3 (5.0–6.0)
0–3 296 (84–1324) 81 (27–139) 6.0 (5.0–8.0) 934 (489–1857) 313 (52–558) 5.5 (5.0–7.5)
3–6 47 (12–432) 109 (82–154) 7.0 (5.0–7.5) 434 (145–1034) 592 (213–698) 6.5 (5.0–7.0)
6–12 5 (0a)17) 114 (86–156) 6.5 (4.5–7.0) 87 (33–364) 666 (333–751) 6.3 (5.5–7.0)
12–24 0 (0a)1) 114 (86–156) 6.0 (4.5–7.0) 0 (0b)47) 666 (333–770) 6.0 (5.0–6.5)
aBelow the detection limit of 0.5 mg ⁄L, values set to 0.
bBelow the detection limit of 2.5 mg ⁄L, values set to 0.
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Fig. 2. (a) Mean of the ten subjects’
sulphamethizole concentration
curves related to the distribution of
sulphamethizole MICs for E. coli
strains (n ¼ 147) from urinary tract
infections in general practice. Ar-
rows indicate the MIC50 and MIC90
values. Error bars indicate the stand-
ard deviation. (b) Mean of the nine
subjects’ mecillinam concentration
curves related to the distribution of
mecillinam MIC values in E. coli
strains (n ¼ 147) from urinary tract
infections in general practice.
Arrows indicate the MIC50 and
MIC90 values. Error bars indicate
the standard deviation.
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Fig. 3. (a) The mean effect of sulphamethizole urine samples (n ¼ 10) on three E. coli strains after 2.5 h and 5 h. The
D log10 CFU ⁄mL is calculated as the difference between the CFU ⁄mL of the sample and the CFU ⁄mL of the control at
the same time. p values are indicated on the figure: *p ¼ 0.01–0.05, **p ¼ 0.001–0.01, ***p ¼< 0.001. Error bars indicate the
standard deviation. (b) The mean effect of mecillinam urine samples (n ¼ 9) on three E. coli strains after 2.5 h and 5 h.
The D log10 CFU ⁄mL is calculated as the difference between the CFU ⁄mL of the sample and the CFU ⁄mL of the control at
the same time. p values are indicated on the figure: *p ¼ 0.01–0.05, **p ¼ 0.001–0.01, ***p ¼< 0.001. Error bars indicate the
standard deviation.
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intervals. At both time points, growth was inhib-
ited in all samples, except in the 12–24-h sample,
where strains V and VI grew almost like the
control.
Correlation between ex-vivo effect and MIC
Fig. 4 shows the correlation between the ex-vivo
effect (D log10 CFU ⁄mL) and the log10 concentra-
tion ⁄MIC ratio for all combinations of strains and
collection intervals for sulphamethizole and me-
cillinam after exposure for 5 h. The concentrations
of antibiotic were adjusted, since the urine sam-
ples were diluted by 10% after addition of the
inoculum. The strain with a sulphamethizole MIC
> 2048 mg ⁄L was set to 4096 mg ⁄L in the calcu-
lations.
For sulphamethizole, there was a slight but
significant correlation between the two varia-
bles (r2 ¼ 0.27, p < 0.0001), and a significant
correlation was seen with mecillinam (r2 ¼ 0.66,
p < 0.0001). Some strains were affected even
though the antibiotic concentration was below
the MIC. The corresponding relationships after
exposure for 2.5 h were r2 ¼ 0.06, p < 0.01 for
sulphamethizole and r2 ¼ 0.42, p < 0.0001 for
mecillinam (data not shown).
D I S C U S S I O N
Despite use since the 1930s, there are only limited
data available on the concentrations in urine of
antibiotics belonging to the sulphamethizole group
[10], and it is usually stated that the concentrations
are high (c. 200–400 mg ⁄L) [11,12]. While the
excretion of mecillinam has been studied more
thoroughly since its introduction in the 1970s, fewer
data are available on its concentration in urine.
In this study, 6 h after an oral dose of 400 mg of
pivmecillinam had been given to normal subjects,
c. 40% of the dose was excreted in the urine as
mecillinam, after which the excretion declined, as
reported elsewhere [5,13–15]. Other studies have
reported excretion to be 25–30% [16,17], which
could be explained by the rapid degradation of
mecillinam in samples. The actual concentration
of mecillinam in urine after oral administration of
400 mg of pivmecillinam has been reported to
vary from 92 to 365 mg ⁄L [17] and from 37 to
787 mg ⁄L (mean: 187 mg ⁄L) [18] in the first 6-h
pooled urine sample. A study in which 400 mg of
pivmecillinam was administered four times daily
showed a mean mecillinam concentration in urine
over 24 h of c. 300 mg ⁄L [19]. The present study
revealed the same degree of variability in the level
of urine concentrations after one dose as did the
above mentioned studies, but also shows that the
peak concentration occurs in the first 3 h after
ingestion.
In a South African study, the maximum 6-h
sulphamethizole urine level was measured, and a
mean of 374 mg ⁄L was found (range 64–768 mg ⁄L),
after an oral dose of 160 mg of sulphamethizole
[7]. In a Danish experiment, 500 mg of sulphame-
thizole was given orally four times daily, yielding
urine concentrations of 200–12 000 mg ⁄L [20]. It is
unclear whether, in these studies, all excreted
urine was collected or merely samples at indica-
ted times. Therefore, it is difficult to compare the
results with the current data, since all urine was
collected in the present study to give an average
concentration at the collection interval in ques-
tion. To our knowledge, there are no other studies
reporting the urine concentrations of sulphame-
thizole in humans.
The MIC breakpoint should, in theory, be
determined by the pharmacokinetic profile of the
antibiotic at the site of infection and the distribu-
tion of MIC values in pathogens. The current
recommended National Committee for Clinical
Laboratory Standards urinary breakpoint for
sulphonamides is R ‡ 512 mg ⁄L, and for mecilli-
nam it is R ‡ 32 mg ⁄L [21]. The results of the
current study indicate that, with administration of
1 g of sulphamethizole twice-daily, the antibiotic
concentration in the urine would exceed the MICs
of sensitive E. coli for c. 66% of the time. It is also
possible that the urine concentration could exceed
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Fig. 4. Correlation between log10 antibiotic concentration
in urine ⁄MIC and D log10 CFU ⁄mL after exposure for 5 h
to sulphamethizole or mecillinam.
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the MIC for the resistant population over a very
short period, 0–3 h after administration. In com-
parison, the current recommended regimen for
treating uncomplicated UTI with pivmecillinam is
400 mg three times daily for 3 days. The observa-
tions in this study indicate that a sensitive E. coli
population should be suppressed by mecillinam
in the urine throughout the 24-h period.
Clinical data have shown that treatment of
uncomplicated UTI with 1 g of sulphamethizole
twice-daily for 1 week resulted in cure rates of
58–74% for resistant strains and 71–97% for
sensitive strains [22,23]. A dose of 1 g of
sulphamethizole three times daily for 14 days
resulted in a total cure rate of 92%, although the
cure rate was only 64% when resistant strains
were involved [24]. Whether the reported strains
were actually resistant, and to what degree, was
not reported. Despite this, there seemed to be an
overall lower cure rate when the pathogen was
found to be resistant in vitro.
A range of clinical trials on mecillinam has been
performed with different dosing regimens and
lengths of treatment. Treatment of uncomplicated
UTI with 400 mg of pivmecillinam three or four
times daily for 7–10 days resulted in cure rates of
87–90% [25–27]. Failures were often observed
with strains that were susceptible in vitro, and
strains resistant in vitro could be cured in vivo, so
laboratory tests did not necessarily predict the
clinical outcome. In general, most investigators do
not take account of the fact that 11% of untreated
women with uncomplicated UTI will have sterile
urine after 1 week, and 47% will recover after
2 weeks [28]. This might explain why some
infections, despite in-vitro resistance, can be
treated in vivo. Recent studies have shown that
3-day courses consisting of pivmecillinam with a
dose of 200 mg three times daily, or only twice-
daily for 5 days, cured 91–100% of patients with
uncomplicated UTI [29–31]. The beneficial effects
reported with the lower dose simply reflect the
fact that halving the dose only decreases the time
above the MIC by one T½, which, according to the
present data, is c. 2 h. A comparison of standard
mecillinam (400 mg three times daily for 3 days)
and sulphamethizole (1 g twice-daily for 6 days)
in the treatment of uncomplicated UTI has been
performed, and showed no significant difference
between the cure rates (90–96%), although no
information was given about the susceptibility of
the strains in this study [32].
A relationship between the bactericidal or
bacteriostatic activities of urine samples contain-
ing excreted antibiotic and the MIC values for
pathogens has been demonstrated for several
antibiotics. Madsen et al. found that excreted
amounts of different sulphonamides inhibited
the growth of a single strain [33], while back-
titration of urine samples containing mecillinam
inhibits bacteria with different MIC values [25].
A clinical study with oxytetracycline demonstra-
ted that activity in the urine separated the cures
from the failures [1]. The association between
the bactericidal titre in urine and MICs for the
tested strains has been established with quinolo-
nes [34,35]. On the other hand, no correlation
could be demonstrated between the time required
to kill 90% of the bacteria, the concentration of
co-trimoxazole, and the organism’s suscepti-
bility [36]. This is consistent with the findings
obtained in the present study, and it is possible
that it might be difficult to obtain such a corre-
lation with bacteriostatic antibiotics because
the effect is much less than with bactericidal
antibiotics.
In conclusion, these observations indicate that
sensitive E. coli populations should be suppressed
by a sufficient sulphamethizole urine concentra-
tion for two-thirds of the time with a dose of 1 g
twice-daily, and by a satisfactory mecillinam
urine concentration throughout the 24-h period
with a dose of 400 mg three times daily. A
correlation between the ex-vivo effect (D log10
CFU ⁄mL) and the log10 concentration ⁄MIC ratio
was observed for both antibiotics, although it was
more pronounced for mecillinam. It seems that
there is a lack of clinical studies focusing on the
relationship between the predictability of in-vitro
susceptibility tests and clinical outcome in UTI.
Some would argue that it would not be ethically
correct to continue treatment of a resistant patho-
gen, but that is, in fact, what is done when
empirical treatment is practised.
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